Clinical Focus
Previous Articles Next Articles
Online:
Published:
Contact:
Abstract: Objective To evaluate the effect of metformin on the overall survival of pancreatic cancer patients. Methods A systematic search was conducted in the published literature on studies on the association between metformin and overall survival benefit in pancreatic cancer patients up to June 2017 from EMBase and PubMed. The identified articles were reviewed for additional references. The most adjusted risk estimates were extracted by two authors and summarized using random effects metaanalysis. The quality of the study was assessed by the NewcastleOttawa Scale (NOS), and the study with score ≥6 was taken as the highquality study.Results Eleven articles were included.The metaanalysis showed that metformin treatment can increase the overall survival (OS) of patients with pancreatic cancer compared with nonmetformin treatment (HR=0.85,95%CI=0.750.95,P=0.006),and in subgroup analysis Asian countries and high quality articles also supported this results. Conclusion Metformin increased the overall survival of pancreatic cancer patients compared with nonmetformin treatment.
Key words: pancreatic neoplasms;metformin, overall survival, meta analysis
He Yong, Ran Lingrong, Li Li, He Qing. Metformin and overall survival benefit in pancreatic cancer patients: a meta analysis[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2017.11.016.
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2017.11.016
http://www.lchc.cn/EN/Y2017/V32/I11/981